Loading ETF research
Fetching the latest fund profile, holdings, and market data.
Loading ETF research
Fetching the latest fund profile, holdings, and market data.

Chicago Board Options ExchangeEquity ETF
$38.0663
−$1.3381 · -3.40%
As of Oct 30, 3:37 PM ET
Regular session · ET · Market data may be delayed.
GNMXtargets pure-play or the top 10 companies materially involved ingenomics and precision medicine, including those focused on gene sequencing, molecular diagnostics, gene editing and therapy, targeted treatments, and related healthcare technologies.The fund considers companies deriving significant revenue from this theme, spanningthose thatsupport personalized medicine through bioinformatics, clinical data platforms, laboratory tools, and services that improve disease detection, patient stratification, and treatment development.Using a bottom-up approach that combines fundamental analysis with thematic and quantitative screening, the fund invests in US and international stocks of any market capitalization. Otherfactors include supply chain positioning, growth potential, and valuation. Up to 15% may beallocatedto illiquid investments, including passive minority interests in SPVs. Holdings may include cash, cash equivalents, or short-term US treasuries for liquidity or portfolio management.
Fund facts updated Oct 30, 2026.
Day range
Current $38.0663
52-week range
Current $38.0663
1 month
-0.74%
3 months
+28.08%
Since inception
+455.71%
Cumulative price changes exclude distributions and investor-specific taxes, trading costs, and cash flows.
Showing 15 of 59 reported holdings
Holdings data updated Oct 30, 2026.
Signed exposures may include leverage or short positions and do not represent ordinary portfolio weights.
Continue in GoAI
Connect this ETF with broader market context and continue your research in GoAI.
ETF data may be delayed, incomplete, or revised. Holdings and exposures change over time. Historical performance does not guarantee future results. This page is for informational and educational purposes only and does not constitute investment advice or a recommendation.